topics / مواضيع

  Lenalidomide (continued) ▶ Hormone replacement therapy is predicted to increase the risk of venous thromboembolism when given with r lenalidomide. Theoretical Lenvatinib → see TABLE 9 p. 1377 (QT-interval prolongation) Lercanidipine → see calcium channel blockers Letermovir ▶ Letermovir is predicted to increase the concentration of antiarrhythmics (amiodarone).oTheoretical ▶ Antiepileptics (carbamazepine, phenobarbital, primidone) are predicted to decrease the concentration of o letermovir. Theoretical ▶ Letermovir is predicted to decrease the concentration of antiepileptics (fosphenytoin, phenytoin) and antiepileptics (fosphenytoin, phenytoin) are predicted to decrease the concentration of letermovir.oTheoretical ▶ Letermovir slightly decreases the exposure to antifungals, azoles (voriconazole).oStudy ▶ Letermovir is predicted to increase the concentration of antihistamines, non-sedating (fexofenadine).oTheoretical ▶ Letermovir is predicted to increase the concentration of bosentan.

  is predicted to increase the exposure to aliskiren. Theoretical ▶ Antacids are predicted to decrease the absorption of lapatinib. Avoid.oTheoretical ▶ Antiarrhythmics (dronedarone) are predicted to increase the exposure to lapatinib.oStudy → Also see TABLE 9 p. 1377 ▶ Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to lapatinib. Avoid.rStudy ▶ Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to Study → Also see TABLE 9 p. 1377 lapatinib.o ▶ Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to o lapatinib. Avoid. Study → Also see TABLE 9 p. 1377 ▶ Lapatinib is predicted to increase the exposure to antihistamines, non-sedating (fexofenadine).oTheoretical ▶ Aprepitant o is predicted to increase the exposure to lapatinib. Study ▶ Lapatinib is predicted to increase the exposure to beta blockers, non-selective (nad